Página principal > Resultados de la búsqueda: Herbst, Roy S
  Consejos para la búsqueda
Búsqueda avanzada
Buscar colecciones:
Ordenar por: Mostrar resultados: Formato de visualización:
Resultados globales: 5 registros encontrados en 0.01 segundos.
Artículos, Encontrados 5 registros
Artículos Encontrados 5 registros  
1.
11 p, 379.4 KB Postoperative Chemotherapy Use and Outcomes From ADAURA : Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC / Wu, Yi-Long (Guangdong Lung Cancer Institute) ; John, Thomas (Austin Health) ; Grohe, Christian (Evangelische Lungenklinik) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Goldman, Jonathan W. (University of California) ; Kim, Sang-We (University of Ulsan) ; Kato, Terufumi (Kanagawa Cancer Center) ; Laktionov, Konstantin (Blokhin National Medical Research Center of Oncology) ; Vu, Huu Vinh (Choray Hospital) ; Wang, Zhije (Chinese Academy of Medical Sciences) ; Lu, Shun (Shanghai Jiao Tong University) ; Lee, Kye Young (Konkuk University Medical Center) ; Akewanlop, Charuwan (Siriraj Hospital) ; Yu, Chong-Jen (National Taiwan University College of Medicine) ; de Marinis, Filippo (European Institute of Oncology) ; Bonanno, Laura (Istituto Oncologico Veneto) ; Domine, Manuel (Instituto de Investigación Sanitaria-Fundación Jiménez Díaz) ; Shepherd, Frances A. (University of Toronto) ; Zeng, Lingmin (AstraZeneca) ; Atasoy, Ajlan (AstraZeneca) ; Herbst, Roy S. (Yale School of Medicine) ; Tsuboi, Masahiro (National Cancer Center Hospital East) ; Universitat Autònoma de Barcelona
Introduction: Adjuvant chemotherapy is recommended in patients with resected stages II to IIIA (and select IB) NSCLC; however, recurrence rates are high. In the phase 3 ADAURA study (NCT02511106), osimertinib was found to have a clinically meaningful improvement in disease-free survival (DFS) in patients with resected stages IB to IIIA EGFR-mutated (EGFRm) NSCLC. [...]
2022 - 10.1016/j.jtho.2021.10.014
Journal of Thoracic Oncology, Vol. 17 Núm. 3 (march 2022) , p. 423-433  
Registro completo - Creative Commons
2.
11 p, 421.8 KB Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial / Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Goldman, Jonathan W. (David Geffen School of Medicine. University of California Los Angeles) ; John, Thomas (Department of Medical Oncology. Austin Health) ; Grohe, Christian (Klinik fur € Pneumologie-Evangelische Lungenklinik Berlin Buch) ; Laktionov, Konstantin (N.N. Blokhin National Medical Research Center of Oncology (Rússia)) ; Kim, Sang-We (Department of Oncology. Asan Medical Center) ; Kato, Terufumi (Depart-ment of Thoracic Oncology. Kanagawa Cancer Center) ; Vu, Huu Vinh (Department of Thoracic Surgery. Choray Hospital) ; Lu, Shun (Lung Cancer Center. Shanghai Chest Hospital. Shanghai Jiao Tong University) ; Li, Shanqing (Department of Thoracic Surgery. Peking Union Medical College Hospital. Chinese Academy of Medical Sciences) ; Lee, Kye Young (Pre-cision Medicine Lung Cancer Center. Konkuk University Medical Center) ; Akewanlop, Charuwan (Division of Medical Oncology. Faculty of Medicine. Siriraj Hospital) ; Yu, Chong-Jen (Department of Internal Medicine. National Taiwan University Hospital Hsinchu Branch. National Taiwan University College of Medicine) ; De Marinis, Filippo (Thoracic Oncology Division. European Institute of Oncology (IEO). IRCCS) ; Bonanno, Laura (Medical Oncology 2. Istituto Oncologico Veneto (IOV). IRCCS) ; Domine, Manuel (Hospital Universitario Fundacion Jimenez Díaz. Servicio de Oncología) ; Shepherd, Frances A. (Department of Medical Oncology and Hematology. University Health Network. Princess Margaret Cancer Center. the University of Toronto) ; Atagi, Shinji (Department of Thoracic Oncology. National Hospital Organization Kinki-Chuo Chest Medical Center) ; Zeng, Lingmin (Late Oncology Statistics. AstraZeneca) ; Kulkarni, Dakshayini (Late Oncology R&D. AstraZeneca) ; Medic, Nenad (AstraZeneca Oncology Business Unit. Academy House) ; Tsuboi, Masahiro (Department of Thoracic Surgery and Oncology. National Cancer Center Hospital East) ; Herbst, Roy S. (Medical Oncology. Yale School of Medicine. Yale Cancer Center) ; Wu, Yi-Long (Guangdong Lung Cancer Institute)
Purpose: In the phase III ADAURA trial, adjuvant treatment with osimertinib versus placebo, with/without prior adjuvant chemotherapy, resulted in a statistically significant and clinically meaningful disease-free survival benefit in completely resected stage IB-IIIA EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC). [...]
2022 - 10.1158/1078-0432.CCR-21-3530
Clinical Cancer Research, Vol. 28 Núm. 11 (january 2022) , p. 2286-2296  
Registro completo - Creative Commons
3.
17 p, 534.5 KB COAST : An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination with Oleclumab or Monalizumab in Patients with Unresectable, Stage III Non-Small-Cell Lung Cancer / Herbst, Roy S. (Yale Cancer Center. Smilow Cancer Hospital) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Barlesi, Fabrice (Gustave Roussy) ; Carcereny, Enric (Institut Germans Trias i Pujol. Institut de Medicina Predictiva i Personalitzada del Càncer) ; Chu, Quincy (Cross Cancer Institute) ; Monnet, Isabelle (Centre Hospitalier Intercommunal de Créteil) ; Sánchez Hernández, Alfredo (Consorci Hospitalari Provincial de Castelló) ; Dakhil, Shaker (Cancer Center of Kansas) ; Camidge, D (University of Colorado Anschutz Medical Campus) ; Winzer, Leanne (AstraZeneca) ; Soo-Hoo, Yee (AstraZeneca) ; Cooper, Zachary A. (AstraZeneca) ; Kumar, Rakesh (AstraZeneca) ; Bothos, John (AstraZeneca) ; Aggarwal, Charu (Abramson Cancer Center. University of Pennsylvania) ; Martinez-Marti, Alex (Vall d'Hebron Institut d'Oncologia)
PURPOSEDurvalumab significantly improves overall survival for patients with unresectable stage III non-small-cell lung cancer and no progression after concurrent chemoradiotherapy (cCRT). Building upon that standard of care, COAST is a phase II study of durvalumab alone or combined with the anti-CD73 monoclonal antibody oleclumab or anti-NKG2A monoclonal antibody monalizumab as consolidation therapy in this setting. [...]
2022 - 10.1200/JCO.22.00227
Journal of Clinical Oncology, Vol. 3 (january 2022) , p. JCO.22.00227  
Registro completo - Creative Commons
4.
15 p, 598.6 KB Five Year Survival Update From KEYNOTE-010 : Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC / Herbst, Roy S (Section of Medical Oncology. Yale Comprehensive Cancer Center. Yale University School of Medicine) ; Garon, E.B. (David Geffen School of Medicine. University of California Los Angeles) ; Kim, D.W. (Seoul National University Hospital. Seoul National University College of Medicine) ; Cho, B.C. (Yonsei Cancer Center. Yonsei University College of Medicine) ; Gervais, R. (Centre François Baclesse (Caen, França)) ; Perez-Gracia, J.L. (Clínica Universidad de Navarra) ; Han, J.Y. (Center for Lung Cancer. National Cancer Center) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Forster, M.D. (UCL Cancer Institute/University College London Hospitals) ; Monnet, Isabelle (Centre Hospitalier Intercommunal de Créteil) ; Novello, Silvia (Department of Oncology. University of Turin. Azienda Ospedaliero Universitaria San Luigi) ; Gubens, M.A. (University of California. San Francisco) ; Boyer, M. (Chris O'Brien Lifehouse) ; Su, W.C. (National Cheng Kung University Hospital) ; Samkari, A. (Merck & Co.. Inc.) ; Jensen, E.H. (Merck & Co.. Inc.) ; Kobie, J. (Merck & Co.. Inc.) ; Piperdi, B. (Merck & Co.. Inc.) ; Baas, Pieter (The Netherlands Cancer Institute (Amsterdam, Països Baixos))
Introduction: In the KEYNOTE-010 study, pembrolizumab improved overall survival (OS) versus docetaxel in patients with previously treated, advanced NSCLC with programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) ≥50% and ≥1%. [...]
2021 - 10.1016/j.jtho.2021.05.001
Journal of Thoracic Oncology, Vol. 16 Núm. 10 (october 2021) , p. 1718-1732  
Registro completo - Creative Commons
5.
9 p, 1.3 MB A plain language summary of results from the ADAURA study : osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer / Wu, Yi-Long (Guangdong Lung Cancer Institute. Guangdong Provincial People's Hospital. Guangdong Academy of Medical Sciences) ; Tsuboi, M. (Department of Thoracic Surgery and Oncology. National Cancer Center Hospital East) ; John, T. (Department of Medical Oncology. Austin Health) ; Grohe, C. (Department of Respiratory Diseases. Evangelische Lungenklinik) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Goldman, J.W. (David Geffen School of Medicine. University of California) ; Laktionov, K. (Center of Innovative Technologies and Oncology. N.N. Blokhin Russian Cancer Center. Russian Academy of Medical Sciences) ; Kim, S.W. (Department of Oncology. Asan Medical Center. University of Ulsan. College of Medicine) ; Kato, T. (Department of Thoracic Oncology. Kanagawa Cancer Center) ; Vu, H.V. (Department of Thoracic Surgery. Choray Hospital) ; Lu, S. (Lung Cancer Center. Shanghai Chest Hospital. Shanghai Jiao Tong University) ; Lee, K.Y. (Precision Medicine. Lung Cancer Center. Konkuk University. Medical Center) ; Akewanlop, C. (Division of Medical Oncology. Faculty of Medicine. Siriraj Hospital) ; Yu, C.J. (Department of Internal Medicine. National Taiwan University. Hospital Hsinchu Branch. National Taiwan University. College of Medicine) ; De Marinis, Filippo (Thoracic Oncology Division. European Institute of Oncology (IEO). IRCCS) ; Bonanno, Laura (Medical Oncology 2. Istituto Oncologico Veneto IOV IRCCS) ; Dómine Gómez, Manuel (Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz) ; Shepherd, F.A. (Department of Medical Oncology and Hematology. University Health Network. Princess Margaret Hospital. University of Toronto) ; Zeng, L. (Late Oncology Statistics. AstraZeneca) ; Hodge, R. (Late Oncology Statistics. AstraZeneca) ; Atasoy, A. (Late Oncology Research and Development. AstraZeneca) ; Rukazenkov, Y. (Late Oncology Research and Development. AstraZeneca) ; Herbst, Roy S (Medical Oncology. Yale School of Medicine. Yale Cancer Center)
Here, we summarize the initial results from the ADAURA clinical study looking at treatment with osimertinib in patients with a specific type of non-small cell lung cancer (also called NSCLC). Osimertinib (TAGRISSO®) is a medication used to treat a type of NSCLC with a change (mutation) in the EGFR gene, known as EGFR-mutated NSCLC. [...]
2021 - 10.2217/fon-2021-0752
Future oncology (London, England), Vol. 17 Núm. 35 (december 2021) , p. 4827-4835  
Registro completo - Creative Commons

Vea también: autores con nombres similares
1 Herbst, R.S.
3 Herbst, Roy S.
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.
Depósito Digital de Documentos de la UAB :: Buscar :: Enviar :: Personalizar :: Ayuda
Powered by Invenio v1.1.6
Mantenido por ddd.bib@uab.cat  :: Metadatos sujetos a:
Colaboramos